Immunological Aspects of Approved MS Therapeutics

Paulus S Rommer, Ron Milo, May H Han, Sammita Satyanarayan, Johann Sellner, Larissa Hauer, Zsolt Illes, Clemens Warnke, Sarah Laurent, Martin S Weber, Yinan Zhang, Olaf Stuve

Research output: Contribution to journalReviewResearchpeer-review

71 Downloads (Pure)

Abstract

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.

Original languageEnglish
Article number1564
JournalFrontiers in Immunology
Volume10
Issue numberJuly
Number of pages24
ISSN1664-3224
DOIs
Publication statusPublished - 2019

Fingerprint

ocrelizumab
Pharmaceutical Preparations
Cladribine
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Mitoxantrone
Immune System Diseases
Young Adult

Cite this

Rommer, P. S., Milo, R., Han, M. H., Satyanarayan, S., Sellner, J., Hauer, L., ... Stuve, O. (2019). Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology, 10(July), [1564]. https://doi.org/10.3389/fimmu.2019.01564
Rommer, Paulus S ; Milo, Ron ; Han, May H ; Satyanarayan, Sammita ; Sellner, Johann ; Hauer, Larissa ; Illes, Zsolt ; Warnke, Clemens ; Laurent, Sarah ; Weber, Martin S ; Zhang, Yinan ; Stuve, Olaf. / Immunological Aspects of Approved MS Therapeutics. In: Frontiers in Immunology. 2019 ; Vol. 10, No. July.
@article{5402b59452ce4d7bb4bad0506e1202be,
title = "Immunological Aspects of Approved MS Therapeutics",
abstract = "Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.",
author = "Rommer, {Paulus S} and Ron Milo and Han, {May H} and Sammita Satyanarayan and Johann Sellner and Larissa Hauer and Zsolt Illes and Clemens Warnke and Sarah Laurent and Weber, {Martin S} and Yinan Zhang and Olaf Stuve",
year = "2019",
doi = "10.3389/fimmu.2019.01564",
language = "English",
volume = "10",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",
number = "July",

}

Rommer, PS, Milo, R, Han, MH, Satyanarayan, S, Sellner, J, Hauer, L, Illes, Z, Warnke, C, Laurent, S, Weber, MS, Zhang, Y & Stuve, O 2019, 'Immunological Aspects of Approved MS Therapeutics', Frontiers in Immunology, vol. 10, no. July, 1564. https://doi.org/10.3389/fimmu.2019.01564

Immunological Aspects of Approved MS Therapeutics. / Rommer, Paulus S; Milo, Ron; Han, May H; Satyanarayan, Sammita; Sellner, Johann; Hauer, Larissa; Illes, Zsolt; Warnke, Clemens; Laurent, Sarah; Weber, Martin S; Zhang, Yinan; Stuve, Olaf.

In: Frontiers in Immunology, Vol. 10, No. July, 1564, 2019.

Research output: Contribution to journalReviewResearchpeer-review

TY - JOUR

T1 - Immunological Aspects of Approved MS Therapeutics

AU - Rommer, Paulus S

AU - Milo, Ron

AU - Han, May H

AU - Satyanarayan, Sammita

AU - Sellner, Johann

AU - Hauer, Larissa

AU - Illes, Zsolt

AU - Warnke, Clemens

AU - Laurent, Sarah

AU - Weber, Martin S

AU - Zhang, Yinan

AU - Stuve, Olaf

PY - 2019

Y1 - 2019

N2 - Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.

AB - Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.

U2 - 10.3389/fimmu.2019.01564

DO - 10.3389/fimmu.2019.01564

M3 - Review

C2 - 31354720

VL - 10

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - July

M1 - 1564

ER -

Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L et al. Immunological Aspects of Approved MS Therapeutics. Frontiers in Immunology. 2019;10(July). 1564. https://doi.org/10.3389/fimmu.2019.01564